The broad goals of our project are to pharmacologically optimize, mechanistically characterize (in the most appropriate molecular, cellular and transgenic animal models) and complete the entire preclinical development (through IND filing) of a potent orally bioavailable therapeutic compound carefully selected from a novel series of recently discovered gamma-secretase modulators (GSMs) for the treatment of Alzheimer's disease (AD). AD is neurodegenerative disorder that affects regions of the brain associated with learning and memory. AD affects over 24 million people world-wide and is an enormous burden to society. The extent at which it will affect our aging population will continue to escalate. A recently discovered a series of aryl 2-aminothiazole gamma-secretase modulators (AGSMs) that are pharmaceutical-like small organic molecules that are able to lower Abeta42 production without measurably affecting -Secretase-mediated enzymatic processing of other known gamma-secretase substrates such as the Notch-1 receptor. This project will focus on the pharmacological optimization of a series of AGSMs with improved physicochemical properties known as SGSMs. If successful in a number of predictive preclinical studies, these molecules will undergo further IND-enabling preclinical development and ultimately be tested in humans.
Alzheimer's disease is a major neurodegenerative disease that affects over 24 million people world-wide and currently there is no known cure. This disease if left without an appropriate intervening therapeutic will devastate our Healthcare systems.
|Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent Î³-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9|
|Zhang, Xulun; Hoey, Robert; Koide, Akiko et al. (2014) A synthetic antibody fragment targeting nicastrin affects assembly and trafficking of Î³-secretase. J Biol Chem 289:34851-61|
|Wagner, Steven L; Zhang, Can; Cheng, Soan et al. (2014) Soluble Î³-secretase modulators selectively inhibit the production of the 42-amino acid amyloid Î² peptide variant and augment the production of multiple carboxy-truncated amyloid Î² species. Biochemistry 53:702-13|
|Wagner, Steven L; Tanzi, Rudolph E; Mobley, William C et al. (2012) Potential use of Î³-secretase modulators in the treatment of Alzheimer disease. Arch Neurol 69:1255-8|